Results 11 to 20 of about 80,532 (301)

CAR‐NK cell in cancer immunotherapy; A promising frontier [PDF]

Cancer Science, 2021
AbstractChimeric antigen receptors (CARs) have a unique facet of synthetic biology and offer a paradigm shift in personalized medicine as they can use and redirect the patient's immune cells to attack cancer cells. CAR‐natural killer (NK) cells combine the targeted specificity of antigens with the subsequent intracellular signaling ability of the ...
Faroogh Marofi, Omar F. Abdul‐Rasheed, Heshu Sulaiman Rahman, Hendrik Setia Budi, Abduladheem Turki Jalil, Alexei Valerievich Yumashev, Ali Hassanzadeh, Mahboubeh Yazdanifar, Roza Motavalli, Max Stanley Chartrand, Majid Ahmadi, Angel Cid‐Arreguid, Mostafa Jarahian   +12 more
openaire   +2 more sources

IPSC-derived CAR-NK cells for cancer immunotherapy

Biomedicine & Pharmacotherapy, 2023
Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies. Compared with CAR-T cells, CAR-NK cells have attracted increasing attention owing to their multiple killing mechanisms, higher safety profile, and ...
Xiaotong, Lin, Yao, Sun, Xin, Dong, Zishen, Liu, Ryohichi, Sugimura, Guozhu, Xie   +5 more
openaire   +2 more sources

CAR NK Cells: The Future Is Now

Annual Review of Cancer Biology, 2023
Chimeric antigen receptor (CAR) T cell therapy has been a great success in CD19+ hematological diseases. Natural killer (NK) CAR cells offer an alternative to CAR T cells with an intrinsic potential for universal off-the-shelf cell therapeutics.
Martin J. Raftery, Alexander Sebastian Franzén, Gabriele Pecher   +2 more
openaire   +1 more source

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

Frontiers in Oncology, 2021
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy.
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu, Huafang Wang   +4 more
doaj   +1 more source

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Frontiers in Immunology, 2022
Despite the impressive results of autologous CAR-T cell therapy in refractory B lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost-effective approach with no signs of severe toxicities as described for CAR-T cells.
Antonio Valeri, Antonio Valeri, Almudena García-Ortiz, Almudena García-Ortiz, Eva Castellano, Eva Castellano, Laura Córdoba, Laura Córdoba, Elena Maroto-Martín, Elena Maroto-Martín, Jessica Encinas, Jessica Encinas, Alejandra Leivas, Alejandra Leivas, Paula Río, Joaquín Martínez-López, Joaquín Martínez-López   +16 more
openaire   +4 more sources

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells

Frontiers in Immunology, 2022
Dominant inhibitory receptors for HLA class I (HLA-I) endow NK cells with high intrinsic responsiveness, a process termed licensing or education, but hinder their ability to kill HLA-I+ tumor cells. Cancer immunotherapy with adoptive transfer of NK cells
Xiaoxuan Zhuang, Eric O. Long
doaj   +1 more source

Outsmarting trogocytosis to boost CAR NK/T cell therapy

Molecular Cancer, 2023
AbstractChimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review,
Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown, Hamid Reza Mirzaei   +6 more
openaire   +3 more sources

CAR NK Cell Therapy for T Follicular Helper Cells [PDF]

Cell Reports Medicine, 2020
T follicular helper (TFH) cells are associated with the development of both autoimmune disease and T cell malignancies. In this issue, Reighard et al.,1 describe the design of PD-L1 chimeric antigen receptor (CAR) NK cells that effectively target and eliminate TFH cells.
openaire   +4 more sources

Next-generation cell therapies: the emerging role of CAR-NK cells [PDF]

Hematology, 2020
Abstract T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings ...
Rafet, Basar, May, Daher, Katayoun, Rezvani   +2 more
openaire   +4 more sources